Singapore, May 15 -- US-basedTriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, and South Korea-based International Vaccine Institute (IVI), a non-profit international organisation devoted to and the discovery, development and delivery of vaccines for global health, have signed a Memorandum of Understanding (MoU) to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.

According to the terms of the MoU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives...